Oral immunization with Listeria monocytogenes vaccine enhances immunotherapy for protective immunity in murine models of colorectal cancer Background <p>Colorectal cancer (CRC) is a leading cause of cancer-related death and remains a significant global health challenge. Cancer vaccines have emerged as a promising immunotherapy for long-term tumor control. While <i>Listeria monocytogenes</i> (<i>Lm</i>)-based intravenous vaccines can generate tumor-reactive CD8 T cells, clinical trial success has been limited. Here, we sought to determine whether <i>in vivo</i> targeting of gastrointestinal tissues… Journal for ImmunoTherapy of Cancer February 11, 2026 Original source
Prognostic impact of myelodysplasia-related gene mutations in <i>FLT3</i>-ITD-mutated acute myeloid leukemia <p>Leukemia, Published online: 09 February 2026; <a href="https://www.nature.com/articles/s41375-026-02874-w">doi:10.1038/s41375-026-02874-w</a></p>Prognostic impact of myelodysplasia-related gene mutations in <i>FLT3</i>-ITD-mutated acute myeloid leukemia Leukemia Journal February 11, 2026 Original source
Challenging a clinical dogma with multimodal machine learning: a retrospective analysis of transplant mismatched donor selection <p>Leukemia, Published online: 09 February 2026; <a href="https://www.nature.com/articles/s41375-026-02878-6">doi:10.1038/s41375-026-02878-6</a></p>Challenging a clinical dogma with multimodal machine learning: a retrospective analysis of transplant mismatched donor selection Leukemia Journal February 11, 2026 Original source
Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1–45 years: a Danish cohort study <p>Leukemia, Published online: 10 February 2026; <a href="https://www.nature.com/articles/s41375-026-02873-x">doi:10.1038/s41375-026-02873-x</a></p>Severe toxicity-free survival following acute lymphoblastic leukemia in patients aged 1–45 years: a Danish cohort study Leukemia Journal February 11, 2026 Original source
Correction: Strong constitutive NF-κB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies <p>Leukemia, Published online: 11 February 2026; <a href="https://www.nature.com/articles/s41375-026-02863-z">doi:10.1038/s41375-026-02863-z</a></p>Correction: Strong constitutive NF-κB signaling in B cells drives SLL/CLL-like lymphomagenesis and overcomes microenvironmental dependencies Leukemia Journal February 11, 2026 Original source
Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up† This ESMO Clinical Practice Guideline (CPG) focuses on advanced and metastatic prostate cancer. This includes metastatic castration-sensitive prostate cancer (mCSPC), non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic castration-resistant prostate cancer (mCRPC). The management of early-stage disease is covered in the ESMO CPG for local and locoregional prostate cancer.1 Annals of Oncology February 11, 2026 Original source
Nivolumab plus chemotherapy as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: 5-year follow-up results from CheckMate 649 We report efficacy and safety results from the CheckMate 649 trial after 5 years of follow-up. Annals of Oncology February 11, 2026 Original source
Making Breakthroughs in ALL From Youth to Adulthood <p>When Ann Carroll was diagnosed with cancer at age 28, her dream to get married and have a baby felt out of reach. Now, seven years later and cancer-free, she is living that dream with her husband and their 7-month-old son, Teddy.   “I didn’t think I would get this far,” says Carroll, of Boston, Massachusetts. “My whole journey started when I walked into my doctor’s office because I wasn’t feeling well.”   As a graduate student in 2019 studying clinical psychology at Northwestern University, Carroll started experiencing lightheadedness and tunnel ... <a class="read-more" href="https://blog.dana-farber.org/insight/2026/02/acute-lymphoblastic-leukemia-young-adults-treatment-breakthrough/" title="Making… Dana-Farber Cancer Institute February 11, 2026 Original source
Cell-Death Safety Net a Potential New Cancer Target <p>In the rare event that an elevator cable breaks, modern buildings have additional fail-safe mechanisms. For example, counterweight and mechanical brakes prevent the car from plummeting to the ground.   Similarly, cells have fail-safe mechanisms to prevent them from death under stress, according to new research from the lab of Dana-Farber investigator Loren Walensky, MD, PhD. A well-known process in cells keeps pro-death proteins at bay. Walensky ...… Dana-Farber Cancer Institute February 10, 2026 Original source
Malignant B cells expressing SIRPα are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma <p>Leukemia, Published online: 04 February 2026; <a href="https://www.nature.com/articles/s41375-026-02872-y">doi:10.1038/s41375-026-02872-y</a></p>Malignant B cells expressing SIRPα are highly proliferative and are associated with inferior clinical outcomes in B-cell non-Hodgkin lymphoma Leukemia Journal February 4, 2026 Original source
Safety and efficacy of short courses of antibiotic therapy in high-risk febrile neutropenic pediatric patients <p>Leukemia, Published online: 04 February 2026; <a href="https://www.nature.com/articles/s41375-026-02876-8">doi:10.1038/s41375-026-02876-8</a></p>Safety and efficacy of short courses of antibiotic therapy in high-risk febrile neutropenic pediatric patients Leukemia Journal February 4, 2026 Original source
Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma <p>Leukemia, Published online: 04 February 2026; <a href="https://www.nature.com/articles/s41375-026-02861-1">doi:10.1038/s41375-026-02861-1</a></p>Accumulation of high-risk genetic features after chemoimmunotherapy: A longitudinal study in mantle cell lymphoma Leukemia Journal February 4, 2026 Original source
Redirecting cytomegalovirus immunity against pancreas cancer for immunotherapy Background <p>Immunotherapy has had limited success in pancreatic cancer, largely due to a low mutational burden and immunosuppressive microenvironment. Here we hypothesized that systemic delivery of viral antigens can redirect pre-existing antiviral immunity against pancreatic tumors.</p> Methods <p>Cytomegalovirus (CMV, a β-herpesvirus) was chosen, as the majority of the population is infected and it induces an extremely large/broad memory T-cell response.… Journal for ImmunoTherapy of Cancer February 4, 2026 Original source
Young Cardiac Angiosarcoma Survivor Champions Narrative Medicine <p>Since she was a young child in a family in which Portuguese and German were often spoken, Sarah Downey, 23, has been fascinated with different languages and cultures. Now, as a recent college graduate living with a very rare cancer of the heart known as cardiac angiosarcoma, Downey is committed to helping others facing cancer, along with their providers and… Dana-Farber Cancer Institute February 4, 2026 Original source
Neoadjuvant chemoimmunotherapy in non-small cell lung cancer: evolving resectability criteria, biomarker-driven postoperative management, and emerging therapeutic strategies <p>Neoadjuvant chemoimmunotherapy (chemo-IO) has fundamentally reshaped the treatment paradigm for resectable non-small cell lung cancer (NSCLC), challenging long-held surgical boundaries and redefining what constitutes "resectable" disease. Trials such as CheckMate-816, KEYNOTE-671, and AEGEAN have demonstrated that integrating immune checkpoint blockade with chemotherapy yields unprecedented rates of pathological response and event-free survival, positioning chemo-IO as the new global standard for stage… Journal for ImmunoTherapy of Cancer February 4, 2026 Original source
Synergistic effects of anticoagulants and platelet aggregation inhibitors with immune checkpoint inhibitors in cancer therapy: a comprehensive review of preclinical and clinical evidence Background <p>The rapidly advancing field of cancer therapy has sparked growing interest in the potential synergy between anticoagulation and immune checkpoint inhibitor (ICI) therapy. Recent research highlights that anticoagulants, traditionally used for thromboprophylaxis and managing thromboembolic events, may also exhibit immunomodulatory properties. These properties can influence the tumor microenvironment by promoting immune cell infiltration, enhancing antitumor immune responses, and potentially… Journal for ImmunoTherapy of Cancer February 4, 2026 Original source
Dysregulated expression of the tumor suppressor p14ARF in cancer provides an effective target for TCR-T cell therapeutics Background <p>The CDKN2A gene encodes two canonical tumor suppressors, p16INK4A and p14ARF, which safeguard cells from malignant transformation by inducing cell cycle arrest and apoptosis in response to aberrant growth signals. Paradoxically, many cancers overexpress these proteins when downstream effectors that enforce negative feedback regulation are lost or inactivated. For example, p14ARF, which regulates p53 activation, is aberrantly expressed in… Journal for ImmunoTherapy of Cancer February 4, 2026 Original source
Tumor immune microenvironment facilitates resistance to KRAS G12C inhibitor sotorasib by altered PD-L1 expression. Background <p>Acquired resistance to KRAS G12C inhibitor sotorasib remains a critical challenge in non-small cell lung cancer treatment. A deeper, rational understanding of resistance mechanisms can enable the development of therapeutic strategies to overcome resistance.</p> Methods <p>We established a syngeneic resistant model after prolonged AMG-510 treatment in C57BL/6 mice. In addition, the in vitro co-culture model and multiple methods including… Journal for ImmunoTherapy of Cancer February 4, 2026 Original source
Potent antitumor activity through dual targeting of PD-L1 and TGF-{beta} pathways in the glioma tumor microenvironment Background <p>Glioblastoma, one of the most aggressive brain tumors, has been largely resistant to conventional immunotherapies, underscoring the need for novel treatment approaches. A promising strategy involves simultaneously inhibiting immunosuppressive pathways in the tumor microenvironment, as these pathways play pivotal roles in immune evasion. However, the therapeutic potential of combined targeting of these key immunosuppressive pathways in glioblastoma remains underexplored.… Journal for ImmunoTherapy of Cancer February 4, 2026 Original source
Best of 2025 in prostate cancer and prostatic diseases <p>Prostate Cancer and Prostatic Diseases, Published online: 04 February 2026; <a href="https://www.nature.com/articles/s41391-026-01083-x">doi:10.1038/s41391-026-01083-x</a></p>Best of 2025 in prostate cancer and prostatic diseases Prostate Cancer Journal February 4, 2026 Original source